Integrating single-cell and spatial transcriptomes reveals COL4A1/2 facilitates the spatial organisation of stromal cells differentiation in breast phyllodes tumours

Abstract

Background: Breast phyllodes tumours (PTs) are a unique type of fibroepithelial neoplasms with metastatic potential and recurrence tendency. However, the precise nature of heterogeneity in breast PTs remains poorly understood. This study aimed to elucidate the cell subpopulations composition and spatial structure and investigate diagnostic markers in the pathogenesis of PTs.

Methods: We applied single-cell RNA sequencing and spatial transcriptomes on tumours and adjacent normal tissues for integration analysis. Immunofluorescence experiments were conducted to verify the tissue distribution of cells. Tumour cells from patients with PTs were cultured to validate the function of genes. To validate the heterogeneity, the epithelial and stromal components of tumour tissues were separated using laser capture microdissection, and microproteomics data were obtained using data-independent acquisition mass spectrometry. The diagnostic value of genes was assessed using immunohistochemistry staining.

Results: Tumour stromal cells harboured seven subpopulations. Among them, a population of widely distributed cancer-associated fibroblast-like stroma cells exhibited strong communications with epithelial progenitors which underwent a mesenchymal transition. We identified two stromal subpopulations sharing epithelial progenitors and mesenchymal markers. They were inferred to further differentiate into transcriptionally active stromal subpopulations continuously expressing COL4A1/2. The binding of COL4A1/2 with ITGA1/B1 facilitated a growth pattern from the stroma towards the surrounding glands. Furthermore, we found consistent transcriptional changes between intratumoural heterogeneity and inter-patient heterogeneity by performing microproteomics studies on 30 samples from 11 PTs. The immunohistochemical assessment of 97 independent cohorts identified that COL4A1/2 and CSRP1 could aid in accurate diagnosis and grading.

Conclusions: Our study demonstrates that COL4A1/2 shapes the spatial structure of stromal cell differentiation and has important clinical implications for accurate diagnosis of breast PTs.

Keywords

breast phyllodes tumour heterogeneity / fibroepithelial lesions / single-cell RNA sequencing / spatial transcriptome / tumour grading

References

[1] Tse GM, Niu Y, Shi HJ. Phyllodes tumor of the breast: an update. Breast Cancer. 2010;17(1):29-34.

[2] Bernstein L, Deapen D, Ross RK. The descriptive epidemiology of malignant cystosarcoma phyllodes tumors of the breast. Cancer. 1993;71(10):3020-3024.

[3] Liu SY, Joseph NM, Ravindranathan A, et al. Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity. Mod Pathol. 2016;29(9):1012-1027.

[4] Barth RJ. Borderline and malignant phyllodes tumors: how often do they locally recur and is there anything we can do about it? Ann Surg Oncol. 2019;26(7):1973-1975.

[5] Mao Y, Xiong Z, Wu S, et al. The predictive value of magnetic resonance imaging-based texture analysis in evaluating histopathological grades of breast phyllodes tumor. J Breast Cancer. 2022;25(2):117-130.

[6] Kapiris I, Nasiri N, A'Hern R, Healy V, Gui GP. Outcome and predictive factors of local recurrence and distant metastases following primary surgical treatment of high-grade malignant phyllodes tumours of the breast. Eur J Surg Oncol. 2001;27(8):723-730.

[7] Guerrero MA, Ballard BR, Grau AM. Malignant phyllodes tumor of the breast: review of the literature and case report of stromal overgrowth. Surg Oncol. 2003;12(1):27-37.

[8] Lee SE, Bae YK, Choi JH. Pancreatic metastasis from malignant phyllodes tumor of the breast. Yeungnam Univ J Med. 2021;38(1):78-82.

[9] Tan PH. Fibroepithelial lesions revisited: implications for diagnosis and management. Mod Pathol. 2021;34(suppl 1):15-37.

[10] USCAP 2022 abstracts: breast pathology (74-204). Mod Pathol. 2022;35(suppl 2):153-305.

[11] Tan PH, Thike AA, Tan WJ, et al. Predicting clinical behaviour of breast phyllodes tumours: a nomogram based on histological criteria and surgical margins. J Clin Pathol. 2012;65(1):69-76.

[12] Tan BY, Fox SB, Lakhani SR, Tan PH. Survey of recurrent diagnostic challenges in breast phyllodes tumours. Histopathology. 2023;82(1):95-105.

[13] Tan J, Ong CK, Lim WK, et al. Genomic landscapes of breast fibroepithelial tumors. Nat Genet. 2015;47(11):1341-1345.

[14] Sim Y, Ng GXP, Ng CCY, et al. A novel genomic panel as an adjunctive diagnostic tool for the characterization and profiling of breast Fibroepithelial lesions. BMC Med Genomics. 2019;12(1):142.

[15] Otsuji K, Sasaki T, Tanabe M, Seto Y. Droplet-digital PCR reveals frequent mutations in TERT promoter region in breast fibroadenomas and phyllodes tumours, irrespective of the presence of MED12 mutations. Br J Cancer. 2021;124(2):466-473.

[16] Garcia-Dios DA, Levi D, Shah V, et al. MED12, TERT promoter and RBM15 mutations in primary and recurrent phyllodes tumours. Br J Cancer. 2018;118(2):277-284.

[17] Lae M, Gardrat S, Rondeau S, et al. MED12 mutations in breast phyllodes tumors: evidence of temporal tumoral heterogeneity and identification of associated critical signaling pathways. Oncotarget. 2016;7(51):84428-84438.

[18] Yoon N, Bae GE, Kang SY, et al. Frequency of MED12 mutations in phyllodes tumors: inverse correlation with histologic grade. Genes Chromosomes Cancer. 2016;55(6):495-504.

[19] Tsang JYS, Hui YK, Lee MA, et al. Association of clinicopathological features and prognosis of TERT alterations in phyllodes tumor of breast. Sci Rep. 2018;8(1):3881.

[20] Kumar A, Nayakanti DS, Mangalaparthi KK, et al. Quantitative proteome profiling stratifies fibroepithelial lesions of the breast. Oncotarget. 2021;12(5):507-518.

[21] Nie Y, Chen J, Huang D, et al. Tumor-associated macrophages promote malignant progression of breast phyllodes tumors by inducing myofibroblast differentiation. Cancer Res. 2017;77(13):3605-3618.

[22] Nie Y, Huang H, Guo M, et al. Breast phyllodes tumors recruit and repolarize tumor-associated macrophages via secreting CCL5 to promote malignant progression, which can be inhibited by CCR5 inhibition therapy. Clin Cancer Res. 2019;25(13):3873-3886.

[23] Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15-21.

[24] Gaujoux R, Seoighe C. A flexible R package for nonnegative matrix factorization. BMC Bioinf. 2010;11:367.

[25] Wu T, Hu E, Xu S, et al. ClusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation (Camb). 2021;2(3):100141.

[26] Patel AP, Tirosh I, Trombetta JJ, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014;344(6190):1396-1401.

[27] Elosua-Bayes M, Nieto P, Mereu E, Gut I, Heyn H. SPOTlight: seeded NMF regression to deconvolute spatial transcriptomics spots with single-cell transcriptomes. Nucleic Acids Res. 2021;49(9):e50.

[28] Bagaev A, Kotlov N, Nomie K, et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell. 2021;39(6):845-865.e7.

[29] Liberzon A, Birger C, Thorvaldsdottir H, et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417-425.

[30] Prianichnikov N, Koch H, Koch S, et al. MaxQuant software for ion mobility enhanced shotgun proteomics. Mol Cell Proteomics. 2020;19(6):1058-1069.

[31] Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinf. 2013;14:7.

[32] Li X, Vail E, Maluf H, et al. Gene expression profiling of fibroepithelial lesions of the breast. Int J Mol Sci. 2023;24(10):9041.

[33] Hoda SA, Brogi E, Koerner FC, Rosen PP. Rosen's Breast Pathology. 5th ed. Wolters Kluwer Press; 2023.

[34] Jara-Lazaro AR, Tan PH. Molecular pathogenesis of progression and recurrence in breast phyllodes tumors. Am J Transl Res. 2009;1(1):23-34.

[35] Tse GM, Lee CS, Kung FY, et al. Hormonal receptors expression in epithelial cells of mammary phyllodes tumors correlates with pathologic grade of the tumor: a multicenter study of 143 cases. Am J Clin Pathol. 2002;118(4):522-526.

[36] Kim SI, Koo JS. Expression of cancer stem cell markers in breast phyllodes tumor. Cancer Biomark. 2020;29(2):235-243.

[37] Zhang Y, Liss AL, Chung E, Pierce LJ, Kleer CG. Stromal cells in phyllodes tumors of the breast are enriched for EZH2 and stem cell marker expression. Breast Cancer Res Treat. 2016;158(1):21-28.

[38] Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer. 2003;3(5):362-374.

[39] Zheng YQ, Pan YQ, Liao K, et al. Pan-cancer landscape of tumour endothelial cells pinpoints insulin receptor as a novel antiangiogenic target and predicts immunotherapy response. Clin Transl Med. 2023;13(12):e1501.

[40] Chen T, Chen X, Zhang S, et al. The genome sequence archive family: toward explosive data growth and diverse data types. Genomics Proteomics Bioinform. 2021;19(4):578-583.

[41] Ma J, Chen T, Wu S, et al. iProX: an integrated proteome resource. Nucleic Acids Res. 2019;47(D1):D1211-D1217.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.